Editas Medicine, Inc. (EDIT)

NasdaqGS • Currently down 0.17 (-7.16%) in today's trading session

2 members of Congress have disclosed 29 trades in Editas Medicine, Inc. (EDIT) via STOCK Act filings. The most recent disclosure was a sale by Donald S. Beyer on 14 April 2021. The most active traders have been Donald S. Beyer (25) and Donald Sternoff Beyer Jr (4). Aggregate disclosed activity totals roughly $168K in purchases and $64K in sales (midpoint estimates from bracketed disclosure amounts).

Editas Medicine, Inc. is currently trading at $2.27, positioned at 23% of its 52-week range ($1.66 – $4.33).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$2.27
24h Change
-0.17 (-7.16%)
52 Week Range
$1.66–$4.33
View on NASDAQ

Editas Medicine, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for EDIT

Select to highlight on chart
5 transactions
Compliance: 38%
Donald S. Beyer14 Apr 20211 May 2021SaleStock$1,001 - $15,000N/A
Donald S. Beyer2 Mar 20211 Apr 2021SaleStock$1,001 - $15,000N/A
Donald S. Beyer17 Nov 20201 Dec 2020PurchaseStock$1,001 - $15,000N/A
Donald S. Beyer17 Nov 202017 Jul 2021PurchaseStock$1,001 - $15,000N/A
Donald S. Beyer17 Nov 20206 Oct 2021PurchaseStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$348.63M

Volume

2.83M

Beta

2.00

P/E Ratio

-3.03

Fundamentals

EPS

$-0.75

Div. Yield

-

Open

$2.42

Day Range

$2.25 – $2.48

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Gilmore O'Neill
IPO Date
2016-02-03
Website
www.editasmedicine.com

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead...

Earnings

Next Report

Q3 2026

9 Nov

EPS Est.

$-0.21

Rev. Est.

$4.5M

Days Until

25

Recent Quarters

Q2 20265 Aug
EPS$-0.15
Beat 44.5%
Q1 20265 May
EPS$-0.26
Beat 13.3%
Q4 20259 Mar
EPS$-0.06
Beat 77.8%
Q3 202510 Nov
EPS$-0.28
Beat 26.3%
Q2 202512 Aug
EPS$-0.63
Miss 53.7%
Q1 202512 May
EPS$-0.92
Miss 63.1%
Q4 20245 Mar
EPS$-0.55
Miss 41.0%
Q3 20244 Nov
EPS$-0.75
Beat 1.3%
Q2 20247 Aug
EPS$-0.82
Miss 18.8%
Q1 20248 May
EPS$-0.76
Miss 20.6%
Q4 202328 Feb
EPS$-0.23
Beat 55.8%
Q3 20233 Nov
EPS$-0.55
Beat 14.1%
Q2 20232 Aug
EPS$-0.56
Beat 26.3%
Q1 20235 May
EPS$-0.71
Beat 10.1%
Q4 202222 Feb
EPS$-0.88
Miss 4.8%
Q3 20222 Nov
EPS$-0.81
Beat 6.9%
Q2 20223 Aug
EPS$-0.78
Beat 7.1%
Q1 20224 May
EPS$-0.74
Beat 8.6%
Q4 202124 Feb
EPS$-0.61
Beat 21.8%
Q3 20218 Nov
EPS$-0.57
Beat 33.7%
Q2 20214 Aug
EPS$-0.81
Beat 4.7%
Q1 20215 May
EPS$-0.86
Miss 13.2%
Q4 202025 Feb
EPS$-1.00
Miss 21.9%
Q3 20205 Nov
EPS$0.12
Beat 118.8%
Q2 20206 Aug
EPS$-0.43
Beat 46.3%
Q1 20207 May
EPS$-0.69
Beat 11.5%
Q4 201926 Feb
EPS$-0.74
Miss 311.4%
Q3 201912 Nov
EPS$-0.66
Beat 9.6%
Q2 20196 Aug
EPS$-0.69
Miss 16.9%
Q1 20197 May
EPS$-0.60
Miss 5.3%
Q4 201828 Feb
EPS$-0.52
Miss 8.3%
Q3 20187 Nov
EPS$-0.32
Beat 55.6%
Q2 20186 Aug
EPS$-0.82
Miss 18.8%
Q1 20183 May
EPS$-0.67
Beat 13.0%
Q4 20176 Mar
EPS$-0.84
Miss 6.3%
Q3 20177 Nov
EPS$-0.64
Miss 4.9%
Q2 20179 Aug
EPS$-0.65
Miss 1.6%
Q1 201715 May
EPS$-0.85
Miss 37.1%
Q4 20167 Mar
EPS$-1.10
Miss 66.7%
Q3 20167 Nov
EPS$-0.59
Beat 7.8%
Q2 20169 Aug
EPS$-0.54
Miss 17.4%
Q1 201616 May
EPS$-0.80
Miss 247.8%
Q4 201530 Mar
EPS$-4.05
Miss 678.9%
Q4 20153 Feb
EPS$-0.48
Q1 201530 Jun
EPS$-3.08
Q4 201431 Mar
EPS$-0.34
Q3 201431 Dec
EPS$-1.34
Q2 201430 Sept
EPS$-3.16
Q1 201430 Jun
EPS$-2.77
Q4 201331 Mar
EPS$-2.77

10 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

NVS

Novartis AG

47
$146.88+4.47 (+3.14%)
Healthcare
Held by same politician
Same sector: Healthcare
1 politician
View Stock

NVDA

NVIDIA Corporation

22
$221.30-7.22 (-3.16%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

AAPL

Apple Inc.

17
$342.96+1.69 (+0.50%)
Technology
Held by same politician
1 politician
View Stock

Frequently Asked Questions about EDIT

Which members of Congress have traded EDIT?
2 members of Congress have disclosed 29 trades in Editas Medicine, Inc. (EDIT) under the STOCK Act. The most active traders are Donald S. Beyer and Donald Sternoff Beyer Jr.
When was EDIT most recently disclosed by Congress?
The most recent EDIT disclosure was a sale by Donald S. Beyer on 14 April 2021.
What is the total disclosed congressional trading volume for EDIT?
Members of Congress have disclosed approximately $168K in EDIT purchases and $64K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in EDIT?
This EDIT page updates as soon as new STOCK Act disclosures are filed for Editas Medicine, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.